Skip to main content
. 2020 Sep 7;21(18):6533. doi: 10.3390/ijms21186533

Figure 1.

Figure 1

MS-5 confers drug resistance to ovarian cancer (OC) cells. (A) OC cisplatin-sensitive cells (A2780) were exposed to 5 μM of RJY13 in the presence and absence of MS-5 and levels of cleaved polymerase (PARP) were monitored by PARP ELISA kit. (B) OC cisplatin resistant cells (A2780CisR) were exposed to 5 μM of RJY13 in the presence and absence of MS-5 and levels of cleaved PARP were monitored by immunoblotting. (C) OC cisplatin sensitive cells (A2780) were exposed to different concentrations (1–25 μM) of cisplatin in the presence and absence of MS-5 and levels of cleaved PARP were monitored by immunoblotting. (D) OC cisplatin resistant cells (A2780CisR) were exposed to 1 or 5 μM of RJY13 in the presence and absence of MS-5 and levels of cleaved PARP were monitored by immunoblotting. A2780cisR co-cultured with MS-5 were also exposed to 1, 5, and 25 μM of RJY13 in the presence and absence of oriental mistletoe extract (E3 extract) at 50 μg/mL (D). α-Tubulin was used as a loading control. CC, co-culture.